Merck & Co., Inc.

Equities

MRK

US58933Y1055

Pharmaceuticals

Market Closed - Nyse 21:00:02 22/07/2024 BST 5-day change 1st Jan Change
125.7 USD -0.06% Intraday chart for Merck & Co., Inc. -1.90% +15.29%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
BMO Capital Adjusts Price Target on Merck to $150 From $148 MT
Stocks to watch as Biden, Trump vie for presidency RE
TD Cowen Adjusts Price Target on Merck to $140 From $135 MT
Merck: to present its advances in HIV at AIDS 24 CF
Goldman Sachs Adjusts Price Target on Merck & Company to $145 From $144 MT
Novo owner backs Swiss biotech Asceneuron in $100 million round RE
Sector Update: Health Care Stocks Mixed Premarket Friday MT
Sector Update: Health Care MT
Merck: completes acquisition of EyeBio CF
Merck Completes Eyebiotech Acquisition MT
Immutep Achieves 'Positive' Results From Cohort B of Phase 2B Cancer Trial; Shares Rise Pre-Bell MT
Merck & Co., Inc. completed the acquisition of Eyebiotech Limited. CI
Morgan Stanley Adjusts Price Target on Merck to $134 From $132 MT
Merck: acquires aquatics division of Elanco Animal Health CF
Merck's Animal Health Division Completes $1.3 Billion Acquisition of Elanco Animal Health's Aqua Business MT
Prelude Therapeutics Inks Deal With Merck for Phase 2 Study to Evaluate its SMARCA2 Degrader With Keytruda MT
Stocks to watch as Biden and Trump vie for presidency RE
Merck, Orion Convert Ongoing Collaboration Into Exclusive Global License for Opevesostat MT
Merck: license agreement with Orion Corp. for opevesostat CF
Merck, Orion Convert Collaboration Into Exclusive License DJ
Orion Corporation and MSD Announce Mutual Exercise of Option Providing MSD Global Exclusive Rights to Opevesostat CI
Merck & Co., Inc.(NYSE:MRK) dropped from Russell Top 200 Value Index CI
Merck & Co., Inc.(NYSE:MRK) added to Russell 1000 Dynamic Index CI
Merck & Co., Inc.(NYSE:MRK) dropped from Russell 3000 Value Index CI
Merck & Co., Inc.(NYSE:MRK) dropped from Russell 1000 Value-Defensive Index CI
Chart Merck & Co., Inc.
More charts
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (69.7%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of vaccines (18%); - sale of animal health products (9.4%); - other (2.9%). Net sales are distributed geographically as follows: the United States (45.9%), Europe/Middle East/Africa (24.5%), China (8.8%), Japan (6.1%), Asia/Pacific (6.1%), Latin America (4.3%) and other (4.3%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
125.8 USD
Average target price
143 USD
Spread / Average Target
+13.69%
Consensus
  1. Stock Market
  2. Equities
  3. MRK Stock
  4. News Merck & Co., Inc.
  5. Sector Update: Health Care Stocks Retreat Wednesday Afternoon